Navigation Links
National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair

MOUNTAINSIDE, N.J., Aug. 14 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI.PK), today announced that Michael Cohen, CEO of the Company, and Jacob Cohen, have discovered biomaterial derived from non- embryonic stem cells, which appears to promote tissue repair in various wound care applications.

On July 26, 2007, the Company announced that while using its proprietary embryonic stem cell lines, Michael and Jacob Cohen discovered a group of biomaterials that in preclinical studies appear to increase the rate at which the tissue surrounding a wound heals, and ultimately, the strength of such newly formed tissue. Today, the Company reports that Michael and Jacob Cohen have also been able to derive such tissue repair promoting biomaterials from non-embryonic stem cells, such as umbilical cord blood cells.

The Company has filed provisional patent applications with the United States Patent and Trademark Office, which cover both the July 26, 2007 discovery and the discovery announced today.

According to Michael Cohen "By deriving these novel biomaterials from non- embryonic stem cells, such as umbilical cord blood, we believe we can avoid the costly and time consuming procedures that plague therapies developed from embryonic stem cells. This new discovery gives us the ability to cultivate tissue repair and wound healing products and commence clinical trials of such products in an expedited manner."

National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics, with a particular focus on finding a cure for diabetes. In addition to its work with stem cell therapeutics, the Company is working to leverage the commercial infrastructure and product development capabilities of its wholly-owned subsidiary, The Sperm Bank of NY. The Company's investigational products are focused on the improvement of the quality of life for patients and their families. National Stem Cell Holding, Inc. is headquartered in Mountainside, NJ.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements, which include, but are not limited to statements regarding: the ability of the Company to perform clinical trials, the ability of the biomaterials to promote tissue repair and the variety of wound care applications. All of such forward-looking statements are not guarantees of future performance. They are based on management's current expectations and are subject to risks and uncertainties that are difficult to predict and generally beyond the control of the Company, and that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: the risk that the patent applications will not be granted, the risk that the analysis of future data will not warrant continuation of development; the risk that the FDA, the institutional review boards for the clinical sites or the investigators may not agree with the Company's assessment of the results and may not permit future trials; the risk that concerns may arise from additional analysis or data; and the risk that the Company may encounter other unexpected hurdles. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. National Stem Cell Holding, Inc. does not undertake any obligation to update or revise any forward-looking statements, to reflect changes to management's expectations, change in events, conditions or circumstances after the date hereof, or the occurrence of or non-occurrence of any events, new information or otherwise.

SOURCE National Stem Cell Holding, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
7. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
8. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:10/13/2015)... 2015  Kay Elledge, M.D., an established South ... of Obstetrics and Gynecology (FACOG) for the past ... Genuine Self Medical Laser Center where she provides ... of Breast Cancer Awareness Month , the ... MonaLisa Touch treatments initiated in the month ...
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 /PRNewswire/ ... bioelectronics for use in research and diagnostics, announces ... of $1.6 million led by Serra Ventures. ... Nanomed,s mission is providing low-cost, easy-to-use monitoring and ... personal health decisions. The funding round will enable ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... "My friend's son suffers from eczema, and he had a horrible habit ... Platteville, Colo. "I came up with this kit as a way to prevent children ... child from rubbing or scratching his or her face. This protects sensitive skin from ...
(Date:10/13/2015)... ... , ... ProText Kinetic Panel is a typography creation tool made for use ... energetic text animations in any layout without the use of keyframes. Using ProText Kinetic ... stylize the text. With intuitive on-screen controls, users can re-position and scale the text. ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, ... application, announced today a significant contract that will provide its award-winning private messaging ... build on the growing success of its Relay program, IBX Wire™, which now ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading ... Singal's newly launched "Publish Academy" training course . Singal's new program, in ... enrollment today, and marketers around the Internet are weighing in with reviews. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System ... with more than 59,000 emergency department visits per year, today announced the successful ... to help improve clinical, operational and financial outcomes. , In less ...
Breaking Medicine News(10 mins):